Literature DB >> 9757985

Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model.

B M Casey1, R E Bawdon.   

Abstract

OBJECTIVE: The object was to determine the placental transfer of ritonavir alone and in combination with zidovudine. STUDY
DESIGN: Twelve placental perfusion studies were performed at trough (1-2 microg/mL) and peak (approximately 20 microg/mL) combinations of ritonavir and zidovudine. Accumulation of ritonavir was determined.
RESULTS: Transfer of ritonavir at trough concentrations was undetectable (<0.025 microg/mL). The clearance index of ritonavir at peak concentration was 0.085 +/- 0.05 and was unaffected by zidovudine. The fetal concentration of ritonavir was 0.0758 +/- 0.22 microg/mL at a maternal concentration of approximately 20 microg/mL and 25.5 +/- 6.9 microg/mL at a concentration of 100 microg/mL. There was no tissue accumulation of ritonavir either alone or with zidovudine.
CONCLUSION: The clearance index of ritonavir at therapeutic levels was extremely low, with little accumulation in the fetal compartment and no accumulation in placental tissue. Zidovudine does not significantly affect the transfer or accumulation of ritonavir.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757985     DOI: 10.1016/s0002-9378(98)70078-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  Differential bidirectional transfer of indinavir in the isolated perfused human placenta.

Authors:  Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.

Authors:  Laurent Mandelbrot; Dominique Duro; Emilie Belissa; Gilles Peytavin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

Review 3.  Antiretroviral therapy in pregnancy: a focus on safety.

Authors:  G P Taylor; N Low-Beer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Authors:  J W Smit; M T Huisman; O van Tellingen; H R Wiltshire; A H Schinkel
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.

Authors:  Hélène Chappuy; Jean-Marc Tréluyer; Vincent Jullien; Jérôme Dimet; Elisabeth Rey; Maria Fouché; Ghislaine Firtion; Gérard Pons; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.

Authors:  Sreeja Sudhakaran; Craig R Rayner; Jian Li; David C M Kong; Neil M Gude; Roger L Nation
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

Review 7.  Drug transfer and metabolism by the human placenta.

Authors:  Michael R Syme; James W Paxton; Jeffrey A Keelan
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.

Authors:  Abhishek Gulati; Phillip M Gerk
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

Review 9.  Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

Authors:  Shelley A McCormack; Brookie M Best
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

Review 10.  Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?

Authors:  Claire Thorne; Marie-Louise Newell
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.